Last reviewed · How we verify
continuous infusion of intravenous ketamine
continuous infusion of intravenous ketamine is a NMDA receptor antagonist Small molecule drug developed by Ciusss de L'Est de l'Île de Montréal. It is currently FDA-approved for Induction and maintenance of general anesthesia, Acute pain management, Treatment-resistant depression (off-label/investigational use).
Ketamine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that blocks glutamate signaling in the central nervous system.
Ketamine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that blocks glutamate signaling in the central nervous system. Used for Induction and maintenance of general anesthesia, Acute pain management, Treatment-resistant depression (off-label/investigational use).
At a glance
| Generic name | continuous infusion of intravenous ketamine |
|---|---|
| Sponsor | Ciusss de L'Est de l'Île de Montréal |
| Drug class | NMDA receptor antagonist |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia, Pain Management, Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Ketamine binds to the phencyclidine binding site within the NMDA receptor ion channel, blocking the flow of ions and preventing excitatory neurotransmission. When administered as a continuous intravenous infusion, it produces dissociative anesthesia, analgesia, and rapid-onset antidepressant effects through both NMDA antagonism and modulation of other neurotransmitter systems including monoamines and opioid pathways.
Approved indications
- Induction and maintenance of general anesthesia
- Acute pain management
- Treatment-resistant depression (off-label/investigational use)
Common side effects
- Dissociation
- Increased heart rate and blood pressure
- Nausea and vomiting
- Dizziness
- Hallucinations
- Emergence reactions
Key clinical trials
- Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
- Ketamine Treatment of Youth Suicide Attempters (PHASE3)
- An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyperactive Delirium (PHASE4)
- Ketamine Administration for Postoperative Pain Management in Patients Undergoing Knee Arthroplasty (NA)
- Ultrasound Guided Pecs Block and Ketamine Infusion for Preventing Chronic Pain in Patients Undergoing Breast Cancer Surgery (NA)
- Intravenous Lidocaine Plus Port-Site Ropivacaine for Recovery After Laparoscopic Surgery (PHASE3)
- Effect of Continuous Intraoperative Esketamine Infusion on Perioperative Negative Emotions in Breast Cancer Surgery Patients With Mild-to-Severe Depression (NA)
- Intravenous Lidocaine, Ketamine, and Magnesium in Thoracic Surgery
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- continuous infusion of intravenous ketamine CI brief — competitive landscape report
- continuous infusion of intravenous ketamine updates RSS · CI watch RSS
- Ciusss de L'Est de l'Île de Montréal portfolio CI
Frequently asked questions about continuous infusion of intravenous ketamine
What is continuous infusion of intravenous ketamine?
How does continuous infusion of intravenous ketamine work?
What is continuous infusion of intravenous ketamine used for?
Who makes continuous infusion of intravenous ketamine?
What drug class is continuous infusion of intravenous ketamine in?
What development phase is continuous infusion of intravenous ketamine in?
What are the side effects of continuous infusion of intravenous ketamine?
What does continuous infusion of intravenous ketamine target?
Related
- Drug class: All NMDA receptor antagonist drugs
- Target: All drugs targeting NMDA receptor
- Manufacturer: Ciusss de L'Est de l'Île de Montréal — full pipeline
- Therapeutic area: All drugs in Anesthesia, Pain Management, Psychiatry
- Indication: Drugs for Induction and maintenance of general anesthesia
- Indication: Drugs for Acute pain management
- Indication: Drugs for Treatment-resistant depression (off-label/investigational use)
- Compare: continuous infusion of intravenous ketamine vs similar drugs
- Pricing: continuous infusion of intravenous ketamine cost, discount & access